(Q30374035)

21 June 2017

title

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. (English)

1 reference

21 June 2017

0 references

16

Vidadi Yusibov

1 reference

21 June 2017

Yoko Shoji

1

1 reference

21 June 2017

Hong Bi

2

1 reference

21 June 2017

Konstantin Musiychuk

3

1 reference

21 June 2017

Amy Rhee

4

1 reference

21 June 2017

April Horsey

5

1 reference

21 June 2017

Gourgopal Roy

6

1 reference

21 June 2017

Brian Green

7

1 reference

21 June 2017

Moneim Shamloul

8

1 reference

21 June 2017

Christine E Farrance

9

1 reference

21 June 2017

Barbara Taggart

10

1 reference

21 June 2017

Nutan Mytle

11

1 reference

21 June 2017

Natalia Ugulava

12

1 reference

21 June 2017

Shailaja Rabindran

13

1 reference

21 June 2017

Vadim Mett

14

1 reference

21 June 2017

Jessica A Chichester

15

1 reference

21 June 2017

language of work or name

English

0 references

publication date

25 December 2008

1 reference

21 June 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

volume

27

1 reference

21 June 2017

issue

7

1 reference

21 June 2017

page(s)

1087-1092

1 reference

The role of cell culture vaccines in the control of the next influenza pandemic.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Preparing for the next pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Host cell-mediated selection of a mutant influenza A virus that has lost a complex oligosaccharide from the tip of the hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Opportunities for recombinant antigen and antibody expression in transgenic plants--technology assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Viral vectors for the expression of proteins in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Immunogenicity of a subunit vaccine against Bacillus anthracis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

A plant-produced plague vaccine candidate confers protection to monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Plant-expressed HA as a seasonal influenza vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

pGreen: a versatile and flexible binary Ti vector for Agrobacterium-mediated plant transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

A launch vector for the production of vaccine antigens in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Transient protein expression in three Pisum sativum (green pea) varieties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

High-level transient expression of recombinant protein in lettuce.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Vaccines for seasonal and pandemic influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Making better influenza virus vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Use of viral vectors for vaccine production in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Confronting potential influenza A (H5N1) pandemic with better vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.108

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.11.108

1 reference

21 June 2017

1 reference